Clover Health Investments (NASDAQ:CLOV) CEO Brady Patrick Priest Sells 98,039 Shares

Clover Health Investments, Corp. (NASDAQ:CLOV) CEO Brady Patrick Priest sold 98,039 shares of the firm’s stock in a transaction dated Wednesday, May 13th. The shares were sold at an average price of $3.52, for a total value of $345,097.28. Following the transaction, the chief executive officer owned 2,040,222 shares in the company, valued at approximately $7,181,581.44. This trade represents a 4.58% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Brady Patrick Priest also recently made the following trade(s):

• On Wednesday, March 4th, Brady Patrick Priest sold 175,000 shares of Clover Health Investments stock. The stock was sold at an average price of $2.17, for a total value of $379,750.00.

Clover Health Investments Stock Performance

CLOV opened at $3.49 on Friday. The company has a market cap of $1.83 billion, a PE ratio of -29.08 and a beta of 2.44. The stock has a 50-day moving average of $2.21 and a 200-day moving average of $2.40. Clover Health Investments, Corp. has a 52-week low of $1.58 and a 52-week high of $3.92.

Clover Health Investments (NASDAQ:CLOV) last announced its earnings results on Wednesday, May 6th. The company reported $0.05 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.07 by ($0.02). Clover Health Investments had a negative return on equity of 16.52% and a negative net margin of 2.58%.The company had revenue of $749.19 million for the quarter, compared to the consensus estimate of $714.89 million. On average, research analysts predict that Clover Health Investments, Corp. will post -0.02 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on the company. Wall Street Zen raised Clover Health Investments from a “sell” rating to a “hold” rating in a research report on Sunday, February 15th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Clover Health Investments in a research note on Friday, March 27th. Canaccord Genuity Group cut their price target on Clover Health Investments from $3.70 to $3.20 and set a “buy” rating for the company in a report on Friday, March 20th. Finally, Leerink Partners lowered their price objective on Clover Health Investments from $3.00 to $2.50 and set a “market perform” rating on the stock in a research report on Thursday, March 5th. One research analyst has rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Clover Health Investments presently has an average rating of “Hold” and an average price target of $2.90.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CLOV. Divisadero Street Capital Management LP bought a new position in shares of Clover Health Investments during the 3rd quarter worth approximately $8,470,000. Principal Financial Group Inc. boosted its stake in Clover Health Investments by 1,590.3% in the 3rd quarter. Principal Financial Group Inc. now owns 485,433 shares of the company’s stock valued at $1,485,000 after buying an additional 456,715 shares in the last quarter. SG Americas Securities LLC grew its position in Clover Health Investments by 104.9% in the fourth quarter. SG Americas Securities LLC now owns 59,046 shares of the company’s stock valued at $139,000 after acquiring an additional 30,223 shares during the period. Choreo LLC raised its stake in Clover Health Investments by 34.9% during the fourth quarter. Choreo LLC now owns 386,922 shares of the company’s stock worth $925,000 after acquiring an additional 100,120 shares in the last quarter. Finally, Swiss Life Asset Management Ltd raised its stake in Clover Health Investments by 53.5% during the third quarter. Swiss Life Asset Management Ltd now owns 17,002 shares of the company’s stock worth $52,000 after acquiring an additional 5,926 shares in the last quarter. Institutional investors own 19.77% of the company’s stock.

Clover Health Investments Company Profile

Clover Health Investments is a technology-driven healthcare company specializing in Medicare Advantage plans for senior populations. The company combines insurance coverage with a proprietary software platform to improve care coordination, outcomes tracking and cost management. By leveraging data analytics, Clover Health aims to deliver personalized care pathways and preventive interventions for its members.

At the core of Clover’s offering is its Clover Assistant platform, which aggregates clinical and claims data from multiple sources to create real-time insights for physicians and care teams.